There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 5 to 1
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 10 to 6
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
OKYO Pharma LTD (AIM:OKYO) Interim Results for the Six Months Ending 30 September 2022
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 15 to 11
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 20 to 16
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
OKYO Pharma Limited (AIM:OKYO) U.S. FDA Clearance of IND Application for OK-101
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) OKYO to Participate at Biotech Showcase
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to